Robert Langreth

Gilead Sciences Inc. is in advanced talks to acquire Ouro Medicines, a closely held company testing novel antibody drugs against autoimmune diseases, according to a person familiar with the negotiations.

ImmunityBio Inc.’s shares plunged after the biotechnology company and its billionaire Executive Chairman Patrick Soon-Shiong were hit with a Food and Drug Administration warning letter for false and misleading promotion of its bladder cancer drug Anktiva.

Merck & Co.’s experimental cholesterol pill slashed levels of the artery-clogging plaque far more than older tablets in the latest study to show it may rival powerful injections for high-risk patients.

Biotech startup ARMR Sciences Inc. said it has begun a human trial of its anti-fentanyl vaccine in an early study that could one day lead to a shot offering months-long protection from the deadly respiratory effects of the powerful synthetic opioid.

Scooping up Centessa gives Lilly a foothold in narcolepsy and a promising new class of wakefulness drugs.

Gilead Sciences Inc. agreed to buy private German biotech Tubulis GmbH in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development, according to people familiar with the matter.

Johnson & Johnson reported first-quarter sales above Wall Street’s expectations and bumped up its outlook for the year, led by strong growth of new cancer medicines and a drug for treatment-resistant depression.

(Bloomberg) -- Johnson & Johnson reported first-quarter sales above Wall Street's expectations and bumped up its outlook for the year, led by strong

Gilead Sciences Inc. said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs.

The New England Journal of Medicine is investigating allegations of research misconduct in a key study used to approve Amgen Inc.’s drug Tavneos.